Our Pipeline

We are advancing a pipeline focused on serious CNS diseases with significant unmet clinical need.


*Status of sGC programs as of January 1, 2021. Represents ongoing phase of development; does not correspond to the initiation or completion of a particular phase.

CY6463 is the revised compound name for IW-6463.  IW-6463 will be referenced in various existing articles, trial descriptions, etc.

Download PDF